Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226255 | 1.00 | HTR2C (0.40) | HTR2CSLC6A4LMNAPOLBNAMPT | |
| SCHEMBL226527 | 1.00 | HTR2C (0.40) | HTR2CSLC6A4LMNAPOLBNAMPT | |
| SCHEMBL4915454 | 0.84 | KMT2A (0.41) | LMNAPOLBGAAALDH1A1OXTR | |
| SCHEMBL7494216 | 0.84 | ALDH1A1 (0.40) | LMNAPOLBGAAALDH1A1OXTR | |
| SCHEMBL4915463 | 0.84 | KMT2A (0.41) | LMNAPOLBGAAALDH1A1OXTR | |
| SCHEMBL1022362 | 0.82 | ALDH1A1 (0.38) | HTR2CSLC6A4GAAALDH1A1ASGR1 | |
| SCHEMBL1022363 | 0.82 | ALDH1A1 (0.38) | HTR2CSLC6A4GAAALDH1A1ASGR1 | |
| SCHEMBL12184848 | 0.81 | LMNA (0.41) | LMNAPOLBALDH1A1OXTRKMT2A | |
| SCHEMBL27308751 | 0.80 | MEN1 (0.36) | LMNAPOLBGAAALDH1A1OXTR | |
| SCHEMBL283816 | 0.79 | LMNA (0.38) | LMNAPOLBGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | HTR2C 87/4885SLC6A4 590/4885LMNA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.